Skip to content

Study · Measured the body's own peptide · 2022

2 results

Comparison of frailty in patients with nontuberculous mycobacterial lung disease and bronchiectasis: a prospective cohort study.

Fujita K, Ito Y, Yamamoto Y, Kanai O, Imakita T, Oi I, Ito T, Saito Z, Mio T

BMC pulmonary medicine3 Nov 2022Cited by 2 (Europe PMC)

PMID36329435 (opens in a new tab)PMCIDPMC9632157 (opens in a new tab)DOI10.1186/s12890-022-02206-5 (opens in a new tab)PepBankPUB-36329435
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

BackgroundThe incidence of nontuberculous mycobacterial lung disease (NTM-LD) peaks in middle- and old age groups, coinciding with senescence; thus, chronic infectious diseases can accelerate frailty and worsen mental health in the elderly. In this study, we aimed to compare the prevalence of physical and psychiatric frailty between patients with NTM-LD and bronchiectasis (BE).MethodsThe Kihon Checklist Questionnaire (KCQ) was used to assess physical and psychiatric frailties and identify those at risk of requiring care among patients with newly diagnosed NTM-LD and BE. Additionally, the Hospital Anxiety and Depression Scale (HADS) scores and chronic inflammatory biomarkers of the alveolar region (surfactant protein [SP]-A, SP-D, and human cationic antibacterial protein [hCAP]/LL-37) were assessed and compared between NTM-LD and BE patients.ResultsThere were no significant differences in the background characteristics between the 33 NTM and 36 BE patients recruited. The KCQ revealed that the proportion of frail NTM patients at diagnosis was higher than that of frail BE patients (48.5% vs. 22.2%, p = 0.026). HADS scores were significantly higher in the NTM group than in the BE group (p < 0.01). Bronchoalveolar lavage fluid (BALF) hCAP/LL-37 and SP-D levels were significantly higher (p = 0.001), but serum hCAP/LL-37 levels were significantly lower in the NTM group than in the BE group (p = 0.023). However, there were no significant differences in the BALF and serum SP-D levels between the two groups.ConclusionsThe number of frail NTM patients at diagnosis was significantly higher than that of frail BE patients. Biomarker analysis suggested that the former had more localized lung inflammation than the latter.Trial registrationThis trial was prospectively registered in the Clinical Trials Registry (UMIN 000027652).
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

No result from this study comes from a test of the peptide.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In patients with newly diagnosed nontuberculous mycobacterial lung disease, lung lavage fluid levels of the body's own hCAP/LL‑37 were higher than in patients with bronchiectasis.

    In plain wordsIn lung disease from nontuberculous mycobacteria, the body's own LL‑37 in lung fluid was higher than in bronchiectasis.

    Peptide
    LL-37
    Outcome
    IncreaseBALF hCAP/LL-37 in NTM-LD versus bronchiectasis
    Study

    n = 69

    Comparator
    Bronchiectasis patients
    Outcome group
    Inflammation markers · Respiratory

    Measurements

    p value
    0.001 p
    BALF hCAP/LL-37

    Source sentences

    Summary
    Bronchoalveolar lavage fluid (BALF) hCAP/LL-37 and SP-D levels were significantly higher (p = 0.001), but serum hCAP/LL-37 levels were significantly lower in the NTM group than in the BE group (p = 0.023).
    1 context sentence
    Summary · context
    There were no significant differences in the background characteristics between the 33 NTM and 36 BE patients recruited.

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    In patients with newly diagnosed nontuberculous mycobacterial lung disease, serum levels of the body's own hCAP/LL‑37 were lower than in patients with bronchiectasis.

    In plain wordsIn lung disease from nontuberculous mycobacteria, the body's own LL‑37 in blood was lower than in bronchiectasis.

    Peptide
    LL-37
    Outcome
    DecreaseSerum hCAP/LL-37 in NTM-LD versus bronchiectasis
    Study

    n = 69

    Comparator
    Bronchiectasis patients
    Outcome group
    Inflammation markers · Respiratory

    Measurements

    p value
    0.023 p
    serum hCAP/LL-37

    Source sentences

    Summary
    Bronchoalveolar lavage fluid (BALF) hCAP/LL-37 and SP-D levels were significantly higher (p = 0.001), but serum hCAP/LL-37 levels were significantly lower in the NTM group than in the BE group (p = 0.023).
    1 context sentence
    Summary · context
    There were no significant differences in the background characteristics between the 33 NTM and 36 BE patients recruited.

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.